A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Solid Tumors
Interventions: DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + fulvestrant dose expansion|DRUG: PF-07104091 + PF-07220060 + letrozole dose expansion|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation|DRUG: PF-07220060 + PF-07104091 combination dose escalation
Sponsor: Pfizer